Global and local epidemiology of Group A Streptococcus indicates that naturally-acquired immunity is enduring and strain-specific

TL;DR

This study uses an agent-based model to show that immunity to Group A Streptococcus is long-lasting and strain-specific, which has important implications for vaccine development and understanding disease epidemiology.

Contribution

It provides the first comprehensive modeling evidence that GAS immunity is enduring and strain-specific, clarifying epidemiological patterns and guiding vaccine strategies.

Findings

GAS infection confers long-lasting strain-specific immunity

Limited cross-protection explains strain diversity and prevalence

Vaccine success depends on eliciting cross-protective immunity

Abstract

The bacterium Group A Streptococcus (Streptococcus pyogenes, GAS) is a human-specific pathogen and a major cause of global morbidity and mortality. Despite decades of research our knowledge of GAS infection and immunity is incomplete, hampering vaccine design and other efforts to reduce disease prevalence. Epidemiological studies indicate positive associations between the prevalence of GAS-related disease, the diversity of circulating strains and the degree of poverty in host populations. However, the infection and immune mechanisms underlying these associations are not clear. In this work, we use an agent-based model to demonstrate that observed diversity and prevalence are best accounted for by the hypothesis that GAS infection confers enduring strain-specific immunity, with reduced or absent cross-protection against infection by other strains. Our results suggest that the success of GAS vaccines will depend on their ability to elicit long-lasting cross-protective immunity over multiple strain types.